Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFO-simtuzumab
- Development stage
- Preclinical
- Lead developer
- University of Chicago
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
89Zr-DFO-simtuzumab is a zirconium-89 labeled humanized monoclonal antibody conjugate developed as a positron emission tomography (PET) imaging agent (immunoPET tracer) targeting Lysyl Oxidase-Like 2 (LOXL2). It is prepared by conjugating the anti-LOXL2 monoclonal antibody simtuzumab with the bifunctional chelator desferrioxamine (DFO) and radiolabeling it with zirconium-89. The agent is designed to noninvasively image LOXL2 expression levels in the extracellular matrix (ECM) of solid tumors, such as pancreatic and liver cancers, to assess tumor progression and metastasis. Preclinical studies conducted at the University of Chicago have evaluated its biodistribution, tumor uptake, and imaging potential in xenograft models.
- Other names
- 89Zr-simtuzumab[89Zr]Zr-DFO-simtuzumabzirconium-89-DFO-simtuzumabzirconium89-DFO-simtuzumabzirconium 89-DFO-simtuzumab
02
Targets
LOXL2 (Lysyl oxidase-like 2 protein)
Beyond the preview
Go deeper on 89Zr-DFO-simtuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFO-simtuzumab.